-
Innovation Ranking
Innovation Ranking – SciClone Pharmaceuticals Holding Ltd
SciClone Pharmaceuticals Holdings Ltd (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Thymalfasin in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Thymalfasin in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Thymalfasin in Cystic Fibrosis Drug Details: Thymalfasin (Zadaxin) is a synthetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Thymalfasin in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Thymalfasin in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Thymalfasin in Thymic Carcinoma Drug Details: Thymalfasin (Zadaxin) is a synthetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Thymalfasin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Thymalfasin in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Thymalfasin in Solid Tumor Drug Details: Thymalfasin (Zadaxin) is a synthetic...
-
Product Insights
NewPyelonephritis – Drugs In Development, 2024
Empower your strategies with our Pyelonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in the urethra or bladder and travels up into the kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion, and back or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract, and damage to nerves around the bladder. Treatment includes antibiotics....
-
Product Insights
NewNeuroendocrine Carcinoma – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope...
-
Product Insights
NewHospital Acquired Pneumonia (HAP) – Drugs In Development, 2024
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions. Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia (HAP) drugs in development market research report...
-
Product Insights
NewVentilator Associated Pneumonia (VAP) – Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
NewThymic Carcinoma – Drugs In Development, 2024
Empower your strategies with our Thymic Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Thymic carcinoma is a rare and aggressive cancer that originates from the epithelial cells of the thymus, a gland in the chest that produces immune cells. Thymic carcinoma often spreads to other organs and is resistant to chemotherapy. The symptoms may include chest pain, cough, difficulty breathing, and weight loss. The diagnosis is based on imaging tests and biopsy of the tumor...